• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Novel neoadjuvant immunotherapy treatment and surveillance strategies in resectable esophageal cancer: innovation leads to improved outcomes.

作者信息

Williams Kenneth M, Banks Kian C, Velotta Jeffrey B

机构信息

Department of Thoracic Surgery, Kaiser Permanente Northern California, Oakland, CA, USA.

Department of Surgery, UCSF East Bay, Oakland, CA, USA.

出版信息

J Thorac Dis. 2025 Apr 30;17(4):1802-1806. doi: 10.21037/jtd-24-1867. Epub 2025 Apr 28.

DOI:10.21037/jtd-24-1867
PMID:40400970
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12090161/
Abstract
摘要

相似文献

1
Novel neoadjuvant immunotherapy treatment and surveillance strategies in resectable esophageal cancer: innovation leads to improved outcomes.可切除食管癌的新型新辅助免疫治疗及监测策略：创新带来更好的治疗效果。
J Thorac Dis. 2025 Apr 30;17(4):1802-1806. doi: 10.21037/jtd-24-1867. Epub 2025 Apr 28.
2
Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study.新辅助免疫化疗后行辅助免疫治疗的食管鳞状细胞癌最小残留病指导下的根治性放化疗联合免疫治疗（ECMRD-001）：一项前瞻性队列研究的研究方案
Front Immunol. 2024 Jan 11;14:1330928. doi: 10.3389/fimmu.2023.1330928. eCollection 2023.
3
Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis.新辅助免疫治疗联合化疗治疗可切除食管癌患者的临床和安全性结局评估：系统评价和荟萃分析。
JAMA Netw Open. 2022 Nov 1;5(11):e2239778. doi: 10.1001/jamanetworkopen.2022.39778.
4
TP53-centric ctDNA complements PET/CT for non-invasive assessment of pathological complete response and survival after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a prospective cohort study.以TP53为中心的循环肿瘤DNA（ctDNA）辅助正电子发射断层扫描/计算机断层扫描（PET/CT）对食管鳞状细胞癌新辅助免疫化疗后的病理完全缓解和生存情况进行无创评估：一项前瞻性队列研究
Int J Surg. 2025 May 1;111(5):3256-3268. doi: 10.1097/JS9.0000000000002341.
5
A Phase 1b Clinical Trial of Neoadjuvant Radio-immunotherapy for Esophageal Squamous Cell Cancer.一项新辅助放免疫治疗食管鳞癌的 1b 期临床试验。
Int J Radiat Oncol Biol Phys. 2024 Jul 1;119(3):896-901. doi: 10.1016/j.ijrobp.2023.12.033. Epub 2024 Jan 4.
6
Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non-small cell lung cancer.基于整合模型预测可切除的IIIA期（N2）非小细胞肺癌新辅助免疫治疗的疗效
J Thorac Cardiovasc Surg. 2025 Jan;169(1):242-253.e4. doi: 10.1016/j.jtcvs.2024.05.006. Epub 2024 May 17.
7
Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection.分析新辅助改良 FOLFIRINOX 治疗边界可切除胰腺癌患者的血浆循环肿瘤 DNA：DNA 损伤修复基因改变检测的临床相关性。
Cancer Res Treat. 2023 Oct;55(4):1313-1320. doi: 10.4143/crt.2023.452. Epub 2023 May 4.
8
A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer.可切除局部晚期食管癌新辅助化疗联合新辅助免疫治疗的病例研究。
World J Surg Oncol. 2022 Aug 26;20(1):267. doi: 10.1186/s12957-022-02732-w.
9
Neoadjuvant immunotherapy plus chemotherapy in high altitude natives with resectable esophageal squamous cell carcinoma in Tibet.新辅助免疫疗法联合化疗用于西藏地区可切除食管鳞状细胞癌的高原居民
Asian J Surg. 2024 Dec 6. doi: 10.1016/j.asjsur.2024.11.134.
10
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial.新辅助信迪利单抗联合化疗治疗潜在可切除食管鳞癌患者（KEEP-G 03）：一项开放标签、单臂、Ⅱ期临床试验。
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-005830.

引用本文的文献

1
Development and validation of a prognostic model for overall survival in pN0 esophageal cancer patients after neoadjuvant chemotherapy: a SEER database-based study.新辅助化疗后pN0期食管癌患者总生存预后模型的建立与验证：一项基于监测、流行病学和最终结果（SEER）数据库的研究
J Thorac Dis. 2025 May 30;17(5):3326-3344. doi: 10.21037/jtd-2025-910. Epub 2025 May 27.

本文引用的文献

1
Clinical value of preoperative circulating tumor DNA before surgery in patients with esophageal squamous cell carcinoma.术前循环肿瘤DNA在食管鳞状细胞癌患者手术前的临床价值
Eur J Surg Oncol. 2025 May;51(5):109625. doi: 10.1016/j.ejso.2025.109625. Epub 2025 Jan 21.
2
Efficacy and safety of first-line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma: a network meta-analysis.一线免疫检查点抑制剂联合疗法治疗晚期食管鳞状细胞癌患者的疗效和安全性：一项网状Meta分析
Front Oncol. 2024 Nov 12;14:1369848. doi: 10.3389/fonc.2024.1369848. eCollection 2024.
3
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.
双药化疗、三药化疗或双药化疗联合放疗作为局部晚期食管癌的新辅助治疗（JCOG1109 NExT）：一项随机、对照、开放标签、III 期临床试验。
Lancet. 2024 Jul 6;404(10447):55-66. doi: 10.1016/S0140-6736(24)00745-1. Epub 2024 Jun 11.
4
Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review.饮食因素及其对肿瘤免疫治疗策略的影响：全面综述。
Cell Death Dis. 2024 Apr 9;15(4):254. doi: 10.1038/s41419-024-06641-6.
5
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses.新辅助纳武利尤单抗或纳武利尤单抗联合 LAG-3 抑制剂 relatlimab 治疗可切除食管/胃食管交界处癌：一项 Ib 期试验和 ctDNA 分析。
Nat Med. 2024 Apr;30(4):1023-1034. doi: 10.1038/s41591-024-02877-z. Epub 2024 Mar 19.
6
Adjuvant Immunotherapy in Curative Intent Esophageal Cancer Resection Patients: Real-World Experience within an Integrated Health System.根治性食管癌切除患者的辅助免疫治疗：综合医疗系统中的真实世界经验
Cancers (Basel). 2023 Nov 7;15(22):5317. doi: 10.3390/cancers15225317.
7
Prognostic value of lymph node micrometastasis in esophageal cancer: A systematic review and meta-analysis.食管癌淋巴结微转移的预后价值：一项系统评价与Meta分析
Front Oncol. 2023 Jan 4;12:1025855. doi: 10.3389/fonc.2022.1025855. eCollection 2022.
8
The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020.2020年食管鳞状细胞癌和食管腺癌发病率及死亡率的全球格局以及至2040年的预测：来自GLOBOCAN 2020的新估计
Gastroenterology. 2022 Sep;163(3):649-658.e2. doi: 10.1053/j.gastro.2022.05.054. Epub 2022 Jun 4.
9
Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy.LAG3 在癌症治疗中的分子途径和机制。
Clin Cancer Res. 2022 Dec 1;28(23):5030-5039. doi: 10.1158/1078-0432.CCR-21-2390.
10
Completion of FLOT Therapy, Regardless of Tumor Regression, Significantly Improves Overall Survival in Patients with Esophageal Adenocarcinoma.无论肿瘤退缩情况如何，完成FLOT疗法均可显著提高食管腺癌患者的总生存期。
Cancers (Basel). 2022 Feb 21;14(4):1084. doi: 10.3390/cancers14041084.